Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | LPL | P06858 | 8/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24773231 | 0.87 | LPL (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL26108671 | 0.84 | LPL (0.41) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL30550009 | 0.81 | JAK2 (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL20540203 | 0.81 | LPL (0.39) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL2301628 | 0.81 | JAK2 (0.43) | JAK2BTKLPLLIPGROCK1 | |
| SCHEMBL746647 | 0.81 | JAK2 (0.42) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL22208083 | 0.81 | LPL (0.36) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL29816141 | 0.81 | LPL (0.36) | JAK2BTKLPLLIPGEGFR | |
| SCHEMBL30026022 | 0.81 | LPL (0.46) | JAK2BTKLPLLIPGLIPE | |
| SCHEMBL9786 | 0.81 | LPL (0.46) | JAK2BTKLPLLIPGLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688161-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024206357-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2023177667-A1 | THYROID HORMONE RECEPTOR AGONISTS | BRII BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3697865-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2022-12-28 | — | — | EP | disclosed |
| EP-3700997-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-12-08 | — | — | EP | disclosed |
| EP-3700997-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-12-08 | — | — | EP | disclosed |
| EP-3673031-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3700997-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-3697865-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3473620-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| WO-2019076844-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
| EP-3473620-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-04-24 | — | — | EP | disclosed |
| WO-2019038377-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
| US-7618972-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618972-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1863795-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | CALABRESE ANDREW ANTONY | 2008-07-10 | — | — | US | disclosed |
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | CALABRESE ANDREW ANTONY | 2008-07-10 | — | — | US | disclosed |
| WO-2006100557-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | JAK2 38/4885BTK 2230/4885LPL 2786/4885 |
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | JAK2 2133/4885BTK 3544/4885LPL 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.